Protagonist Therapeutics discloses limited SVB exposure, $13M at risk out of $231M total

Protagonist Therapeutics, Inc

Cash at SVB approximately $13M as of March 9, 2023; company considers exposure limited.
Third-party investments of ~$218M held at multiple custodians are not directly exposed to SVB liquidity concerns.
Total cash and investments approximately $231M; company notes multiple custodians reduce risk.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.